Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The importance of accurately defining high-risk myeloma and current risk stratification systems

Jill Corre • 30 Aug 2022
IMS 2022
Multiple Myeloma

Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, shares some insights into the importance of accurately identifying and risk stratifying high-risk myeloma patients. Dr Corre also discusses updated risk stratification systems and the role of cytogenetics. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jill Corre

Updates in the genomics of SMM & multiple myeloma
Francesco Maura et al. • 15 Apr 2023
1:57
Using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
Jill Corre • 12 May 2023
2:20
Novel technologies and the prognostic value of identifying subclones in myeloma
Jill Corre • 12 May 2023
2:02
The impact of heterogeneity on outcomes in multiple myeloma
Jill Corre • 30 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals